Title:
小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
Document Type and Number:
Japanese Patent JP6868010
Kind Code:
B2
Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
More Like This:
Inventors:
Andrea, Mare
Weinschenk, Toni
Goldfinger, Valentina
Shall, Oliver
Fritche, jens
Shin, Harpreet
Weinschenk, Toni
Goldfinger, Valentina
Shall, Oliver
Fritche, jens
Shin, Harpreet
Application Number:
JP2018512283A
Publication Date:
May 12, 2021
Filing Date:
September 30, 2016
Export Citation:
Assignee:
Imatics Biotechnology GM Behr
International Classes:
C07K7/06; A61K31/7088; A61K38/08; A61K48/00; A61P35/00; C07K14/725; C07K16/18; C12N5/0783; C12N5/10; C12N15/115; C12N15/12; C12N15/13; C12N15/63; C12P21/02; G01N33/574; G01N33/68
Domestic Patent References:
| JP2014507138A | ||||
| JP2013523082A |
Other References:
Milner, E. et al.,"The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome",Mol. Cell. Proteomics,2013年,Vol. 12,pp. 1853-1864, Supplemental Table S4
Cancer Res.,1997年,Vol.57, No.20,pp.4570-4577
Cancer Res.,1997年,Vol.57, No.20,pp.4570-4577
Attorney, Agent or Firm:
Takashi Shoji
Yuriko Shinobu
Takuya Osugi
Hirata Midori
Yuriko Shinobu
Takuya Osugi
Hirata Midori